P117 Machine-learning derived characteristics associated with tapering TNF inhibitors in individuals with rheumatoid arthritis
Authors: Phillips Thomas , Bhandari Megha , Stammers Matthew , Fraser Simon , George Michael , Lin Sharon , Lwin May , Holroyd Christopher , Edwards Christopher 
Published: April 2023

Background/Aims

Tapering of TNF inhibitor (TNFi) drugs may be considered in some patients to reduce risks and costs. Selecting appropriate patients is not always straightforward and may be influenced by age, sex, comorbidity and disease activity state. We sought to identify predictors for dose tapering in a real-world clinical setting. Algorithmic extraction, selection and analysis of relevant patient sub-cohorts could enable identification of relevant predictors associated with TNFi dose tapering.

Methods

Our institution has a Rheumatology Biologics database running prospectively for over 15 years. Our approach for patients with RA receiving TNFi has been to dose-taper by one third and then 50% if remission achieved (defined as DAS28&lt;2.6 on two occasions more than 6 months apart with no corticosteroid use). Prescribing, disease activity scores and demographics were extracted using SQL along with comorbidity coding, pathology results and anthropometric data. Data were anonymised and analysed in Python 3.8 within our institutions’ Trusted Research Environment (TRE). Pandas, NumPy and StatsModels python packages were used for the analysis in Jupyter notebooks. 49 covariates were considered clinically relevant and included in the regression analysis. Recursive feature elimination (RFE) was performed using logistic regression (LR) with threshold p-value of 0.05. The primary outcome was tapering of TNFi, algorithmically identified by a temporal increase in dosing interval or decrease in dosage. To avoid multiple-drug confounding, only the most recent TNFi data was included for each patient.

Results

663 patients with RA were initiated on TNFi between 5th November 2001 and March 2nd 2020. 491 (74.1%) were female with a mean age of 65.5 (SD ± 14.2) years. 261 (39.4%) received adalimumab, 209 (31.5%) etanercept, 74 (11.2%) infliximab, 82 (12.4%) certolizumab and 37 (5.6%) golimumab. Concurrent methotrexate (MTX) was seen in 34.5% (n = 22), either oral or subcutaneous. There was no change in the likelihood of tapering associated with depression, hypothyroidism, obesity, smoking or seropositivity for RF or anti-CCP. Those taking MTX were more likely to taper their biologics (OR 3.33, 95%CI 1.83-6.09, p = &lt;.000), as were patients who were coded as having type 1 or 2 diabetes (7.4% n = 49, OR 3.23, 95%CI 1.32-8.25, p = 0.011), Higher DAS28 CRP score (OR 0.548, 95%CI 0.38-0.78, p = 0.001), and DAS 28 ESR score (OR 0.71, 95%CI 0.53-0.95, p = 0.021) significantly decreased chance of tapering.

Conclusion

Concurrent methotrexate use increases likelihood of subsequent tapering in patients with RA receiving TNFi. Unexpectedly, patients with diabetes were also more likely to taper, however due to low numbers of patients in this group and the width of confidence intervals this should be interpreted cautiously. As expected, patients with high disease activity scores were less likely to taper. This algorithm driven approach produced results largely in keeping with clinical intuition, however these methods may aid in future selection of tapering cohorts.

Disclosure

T. Phillips: None. M. Bhandari: None. M. Stammers: None. S. Fraser: None. M. George: None. S. Lin: None. M. Lwin: None. C. Holroyd: None. C. Edwards: Other; CE has received fees for advisory boards, speaker’s bureau, research support from Abbvie, Astra Zeneca, BMS Celltrion Chugai, Gilead, Galapagos, GSK, Janssen, Eli Lilly, Pfizer, Roche, Sandoz, Samsung.